Pfizer decided to discontinue the development of its leading weight management candidate. Despite this setback, the company has a deep pipeline of candidates, especially in oncology. Pfizer's ...

NEW YORK, April 23, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock ...

Pfizer PFE will report its first-quarter earnings on April 29, before market open. The Zacks Consensus Estimate for sales and earnings for the first quarter is pegged at $13.88 billion and 67 ...

Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in the Philippines, coinciding with its 175th-year global milestone.

Pfizer is ending the development of its GLP-1 weight loss drug, danuglipron. A patient in a clinical trial experienced a liver injury, potentially due to the drug. Pfizer has a massive pipeline ...

The patient did not experience any liver-related symptoms or side effects, a Pfizer spokesperson said in a statement. They added that the patient's liver enzymes "recovered rapidly" after they ...

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company’s common stock, payable June 13, 2025, to holders of the Common ...

Pfizer on Monday said it would end development of its experimental daily weight loss pill after a patient experienced a liver injury that was potentially caused by the drug in a trial. The patient ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...